GSK5182, 4-hydroxytamoxifen analog, is a specific inverse agonist of estrogen-related receptor γ (ERRγ) that inhibits pro-inflammatory cytokine-induced catabolic factors.
GSK5182, a small-molecule ERRγ inverse agonist, inhibits pro-inflammatory cytokine-induced catabolic factors in mouse articular chondrocytes.[1]
GSK5182 significantly reduces cartilage degeneration in ERRγ-overexpressing mice administered intra-articular Ad-Esrrg.[1]
[1] Yunhui Min, et al. Pharmaceuticals (Basel). 2020 Nov 27;13(12):429.
















